^
    Back
    Association details:
    Biomarker:SLC34A2 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:XMT-1592 (Microtubule inhibitor, NaPi2b-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma

    Published date:
    05/15/2020
    Excerpt:
    XMT-1592 exhibited potent and specific in vivo activity in NaPi2b-expressing tumor xenografts derived from ovarian carcinoma or lung adenocarcinoma.
    DOI:
    10.1158/1538-7445.AM2020-2894